Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced early tender results for its tender offers related to several series of its senior notes. The company is increasing the tender caps for its Pool 1 Notes to $1.65 billion, Pool 2 Notes to $450 million, and Pool 3 Notes to approximately $293.3 million, while the Pool 4 Notes cap remains at $250 million. The total maximum amount for the offers is $2.5 billion. Teva aims to manage and extend its debt maturity profile and plans to fund these offers through proceeds from a recent public offering and cash reserves. Settlement is expected on March 15, 2023, and the offers will expire on March 27, 2023.

Teva Pharmaceuticals, in collaboration with NATCO Pharma, has launched additional strengths of its generic lenalidomide capsules in the U.S., including 2.5 mg and 20 mg doses. This follows the introduction of four other strengths in March 2022, making all formulations of lenalidomide available in the U.S. The generic is critical for treating multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. With nearly 500 generic products, Teva leads the market and holds around 100 pending first-to-file opportunities. Lenalidomide's annual sales reached $2.9 billion as of January 2023, enhancing Teva's position in the generics market.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will have its Chief Financial Officer, Eli Kalif, present at the Barclays Global Healthcare Conference on March 14, 2023, at 10:15 A.M. Eastern Time. Investors can access a live webcast of the presentation via Teva's Investor Relations website. A recorded version will be available within 24 hours and can be accessed for up to 90 days. Teva is recognized for its extensive portfolio of over 3,500 products and plays a crucial role in global healthcare, serving approximately 200 million patients daily.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has initiated tender offers with a maximum purchase price of $2.25 billion to buy back various series of senior notes. The notes include 7.125%, 6.000%, and 4.500% Senior Notes, among others. The offers aim to manage and extend Teva's debt maturity profile and will be funded through a financing transaction expected to raise at least $2.0 billion. The offers are set to expire on March 27, 2023, with an early tender deadline of March 10, 2023. Holders of validly tendered notes will receive accrued interest plus specified consideration.

Teva Pharmaceuticals has announced the presentation of new data on its Digihaler System at the AAAAI 2023 Annual Meeting from February 24-27 in San Antonio, Texas. The data focuses on the smart inhaler’s benefits in asthma management, showcasing findings from the CONNECT2 clinical trial. Highlights include real-world usage patterns, adherence relationships, and barriers to implementing digital inhaler technology. The Digihaler System is touted as the first to provide objective data for personalized asthma treatment. Senior Medical Director Tanisha Hill underscores the importance of this data in enhancing patient care and treatment personalization.

Teva Pharmaceuticals announced the launch of the IMPACT-TD Scale, a standardized assessment for measuring the burden of tardive dyskinesia (TD) beyond just movement severity. Developed in collaboration with the TD community, the scale incorporates insights from patients, caregivers, and healthcare providers. It categorizes TD's impact into various areas such as social, psychological, and vocational aspects, aiming to enhance patient dialogue and comprehensive understanding. With 780,000 affected individuals in the U.S., this tool is expected to improve monitoring and overall management of TD, following a consensus published in the Journal of Clinical Psychiatry in November 2022.

Teva Pharmaceuticals has received FDA approval for AUSTEDO XR (deutetrabenazine) extended-release tablets, a once-daily treatment for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). This new formulation is available in 6 mg, 12 mg, and 24 mg strengths, providing a convenient option that may reduce pill burden for patients. AUSTEDO XR is the only VMAT2 inhibitor with long-term efficacy data for these conditions, offering sustained treatment options. Teva aims to facilitate patient adherence with this innovation, expected to be available in the U.S. later this year.